

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss however arising from or in reliance upon the whole or any part of the contents of this announcement.



Abbisko Cayman Limited
和譽開曼有限責任公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT
THE FIRST PATIENT DOSE OF NEXT-GENERATION EGFR
EXON20INS INHIBITOR ABSK112 COMPLETED
BY ABBISKO THERAPEUTICS

Abbisko Cayman Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd., (“**Abbisko Therapeutics**”), a subsidiary of the Company, announced the first patient dose has been completed in the Phase I clinical trial of next-generation EGFR Exon20ins inhibitor ABSK112 for non-small cells lung cancer (“**NSCLC**”).

This is a voluntary announcement made by the Company. The Group cannot guarantee that EGFR Exon20ins inhibitor (ABSK112) will ultimately be successfully marketed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, February 23, 2024

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Chen Zhui as executive directors; Ms. Tang Yanmin as a non-executive director; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Mr. Wang Lei as independent non-executive directors.

Abbisko Therapeutics Completed the First Patient Dose of Next-generation EGFR Exon20ins Inhibitor ABSK112

On February 23, 2024, Abbisko Therapeutics announced the first patient dose has been completed in the Phase I clinical trial of next-generation EGFR Exon20ins inhibitor ABSK112 for NSCLC.

ABSK112 has received clinical study approval from the China NMPA and U.S. FDA, and the Phase I clinical trials were conducted simultaneously in the U.S. and China.

ABSK112 is a next-generation oral EGFR Exon20ins inhibitor with high potency, high selectivity, and strong brain penetrating ability. In comparison to previously approved and clinically studied 1st generation EGFR Exon20ins inhibitors, ABSK112 in preclinical studies has demonstrated excellent brain penetrating ability, superior selectivity over wild type EGFR, broader spectrum of Exon20ins mutation coverage, and superior in vivo efficacy in various EGFR Exon20ins xenograft models. These findings highlight ABSK112's potential in providing an improved therapeutic window and enhanced efficacy in clinic, positioning it as a next-generation potential best-in-class EGFR Exon20ins inhibitor.

About NSCLC

Lung cancer is the second most common cancer worldwide, with more than two million new cases in 2020, including 227,875 cases in U.S. and 815,563 cases in China, respectively. It ranks first in terms of mortality among cancers, with more than 1.7 million deaths per year, including 138,225 cases in U.S. (7.7%) and 714,699 cases in China (39.8%). NSCLC comprises the vast majority (85%) of all lung cancers. Epidermal growth factor receptor (EGFR) mutations were reported in about 17% and 50% of lung adenocarcinoma in Caucasians and Asians, respectively. EGFR Exon20ins mutations represent approximately 1%-12% of EGFR mutations in patients with NSCLC.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Limited (Stock Code on the Hong Kong Stock Exchange: 2256.HK), is an oncology-focused biopharmaceutical company founded in Shanghai, dedicated to discovering and developing innovative medicines to treat unmet medical needs in China and globally. The company was established by a group of seasoned drug hunters with rich R&D and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of 16 innovative small molecule programs focused on precision oncology and immuno-oncology, including eight clinical stage assets.

Please visit www.abbisko.com for more information.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.